Karim Dabbagh was appointed President and CEO of Second Genome in 2018, which he joined as the Chief Scientific Officer in 2014. Prior to that, he served as Vice President of R&D at Pfizer where he led the Immunoregulation department, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. At Pfizer, he also led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas. Before joining Pfizer, Karim was the founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease.  Leading to that, Karim spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College, London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.

Dr. McClure leads all clinical, clinical operations, and regulatory activities at Second Genome.  He brings more than 20 years of experience in clinical/translational medicine, drug development, and therapeutic strategy, with specific expertise in liver disease, inflammation, thrombosis/coagulation, fibrosis, and infectious diseases.

 During his career, Dr. McClure has played a central role in the clinical development of multiple approved/promising molecules, including Esbriet®/pirfenidone at InterMune (which resulted in an $8.3 billion acquisition by Roche), Andexxa®/andexanet alfa at Portola Pharmaceuticals, and lumicitabine at Alios BioPharma (which resulted in a $1.75 billion acquisition by Johnson & Johnson (JNJ)).   Dr. McClure has also served in roles of increasing responsibility, with his most recent position at JNJ being responsible for all aspects of the simultaneous development of three compounds in the infectious diseases area. He has also co-authored multiple peer-reviewed publications in high impact journals including the New England Journal of Medicine, Hepatology and Circulation.

Prior to joining industry, Dr. McClure worked as a hospitalist after earning a medical doctorate and completing a residency in internal medicine, both at Duke University. He earned a bachelor of science degree in biochemistry and cell biology at the University of California, San Diego.

Anu brings more than 20 years of experience in the biotech industry and leads all corporate development activities including business strategy, partnering, licensing, alliance management and Intellectual Property.  Prior to that, Anu was Chief Business Officer at Invenra, Inc. and led all corporate development activities, most notably executing a major deal with Exelixis, Inc. for up to 7 multispecific antibody programs to bring in non-dilutive funding including pre-clinical, clinical and regulatory milestones up to $131.5M and sales milestones up to $325M for any product, plus single-digit tiered royalties.   Anu was also previously Vice President of Business Development at Arcus Biosciences and led academic partnerships and discussions for R&D partnering.  Prior to Arcus, Anu was Senior Director of Business Development at Sutro Biosciences, where she was responsible for business development, licensing, alliance management and business strategy.  During her time at Sutro, Anu helped to bring in over $150M of non-dilutive funding from partnering transactions with Celgene Corporation and EMD Serono, was involved in the spinout of SutroVax and was part of the strategic team to enable a $26M Series D funding.  Prior to Sutro, Anu was a business development consultant from 2001-2012 where she negotiated many agreements and led strategic projects for Igenica, Bioseek, OncoMed, QLT, Ingenium AG, AGY and Axys/Celera.  She started her career in the biotechnology industry as a molecular biologist at Tularik in 1998. 

Anu received her B.S. degree in Molecular Genetics from The Ohio State University, her M.S. degree in Molecular Biology from Case Western Reserve University where she worked on interferon signal transduction in the lab of Dr. George Stark at the Cleveland Clinic Foundation, and obtained her MBA with high honors from the University of San Francisco.

As Senior Vice President, Finance & Controller, Brian Dowd leads all financial and transactional operations at Second Genome.   He has over 25 years’ experience in financial operations for life science and technology companies with domestic and international operations.  He has lead company’s finance operations through the transition from a private company to a publicly traded company via initial public offerings or acquisitions.

Mr. Dowd started his career at Deloitte and has held a number of senior level financial management positions.  Most recently, through November, 2016, he was Vice President, Controller of Johnson & Johnson's Janssen Pharmaceutical's Alios Biopharma, which was acquired by Johnson & Johnson in November, 2014.  Prior to Johnson and Johnson, he held numerous roles at Codexis, Inc. and prior to Codexis, VeriFone Holdings.

Mr. Dowd received his B.S. degree in Business Administration from California Polytechnic University San Luis Obispo.  He is formerly a member of the Board of Trustees at The Carey School and is presently a Board Member of the Belmont Redwood Shores Little League.

 

Mr. Sjoerdsma brings more than 25 years of experience in human resources to his position, in which he will lead all recruitment, hiring, onboarding, training and organizational development of Second Genome employees. Prior to his current role, Sjoerdsma served in various roles in human resources for Genencor at all stages of its growth – from start-up to publicly traded to its acquisition by DuPoint BioSciences. While at Genencor, he developed a corporate culture that led to the company’s recognition as a “Great Place to Work” in four countries, including awards as the top company of its size by Fortune Magazine and the San Francisco Chronicle. Sjoerdsma earned his master’s degree in business administration from Nova Southeastern University and his bachelor’s degree in economics and business from Cornell College. Sjoerdsma holds an executive certificate in strategy and organization from Stanford University.

Todd DeSantis is Second Genome Co-founder and Vice-President of Informatics. Todd has 17 years of experience designing and implementing bioinformatics solutions for analyzing microbial community dynamics.  At Lawrence Berkeley National Laboratory he led the development of novel microbiome assays and analysis pipelines as a Molecular Microbial Ecology Software Developer. He is the chief architect of GreengenesTM, an international effort to catalog global microbial diversity that provides microbial ecologists with reference databases for DNA quality assessment, alignment and classification. Todd also served as an analyst for the NIH Human Microbiome Project and has published over 60 scientific papers.  At Second Genome, he manages all informatics work including identifying and recruiting microbiome scientist leaders, integration of multi-omics pipelines, cloud deployment for big-data analytics, and therapeutic pathway discovery.